Figure 5.

The anti-tumor effect of CBDCA and anti-PD-1 antibodies as neoadjuvant therapy in TNBC models is CD8⁺ T cell-dependent. Neoadjuvant treatment was applied as illustrated in Figure 3. (A) Anti-CD8 neutralizing antibodies were administered as described. At Day 35 after the primary tumor implantation, tumors were collected for data analysis. (A–C) anti-CD8 neutralizing antibody administration impaired survival rates of tumor-bearing mice treated with CBDCA and anti-PD-1 antibodies. The symbol “*” denotes the difference between CBDCA+α-PD-1+Isotype and CTRL. The symbol “#” denotes the difference between CBDCA+α-PD-1+Isotype and CBDCA+α-PD-1+α-CD8. ^{****, ####}p < 0.0001 by log-rank tests, n = 10 per group from one of triplicated experiments. (D–F) anti-CD8 neutralizing antibody treatment reduced the level of tumor-infiltrating CD8⁺ cells. (G–I) anti-CD8 neutralizing antibody supplement decreased the abundance of tumor-specific IFNγ-producing CD8⁺ T cells measured by ELISpot. D-I, by one-way ANOVA with Bonferroni post-hoc tests, n = 9 per group from one of triplicated experiments. ****p < 0.0001.